🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

SBRT + 💊 in oligomets: 🧍‍♂️2294 pts | 🫁, breast, prostate, colorectal ⚠️Grade 3+ AEs: 1.5% ✅ SBRT Safe with systemic tx! #SBRT #OligoCare #ESTRO25 EORTC ESTRO Ciro Franzese

EXTEND showed us that MDT + ADT > ADT RADIOSA showed MDT + ADT > MDT. STORM / PEACE-V showed ENI + MDT + ADT > MDT + ADT All studies had some novel imaging defined mHSPC (STORM was 100% novel) Can we just accept that MDT (+/- elective RT) + ADT is better than either?!?

Drew Moghanaki “possibility VALOR phIII RCT of surgery vs SABR will show no difference in stage I #lungcancer” #radonc #SABR2025 🇨🇦 🟰several studies showing no diff ⬇️ trends for surgery in 🇺🇸 🤔 sampling LNs in solid dom GGO not needed ⚖️ ?benefit of lobectomy nasser altorki

sciencedirect.com/science/articl…

📍 Great discussions and even greater collaboration at the Masterclass in Uro-Onc! Two inspiring days focused on diagnostic and therapeutic strategies in PCa, organized by the AIRO Uro-Oncology Study Group! Proud to be part of the scientific committee together with these two🩷😃

Pembrolizumab now FDA-approved in resectable LA-HNSCC (KEYNOTE-689): ✔️ Median EFS: 51.8 vs 30.4 mo (HR: 0.73) ✔️ Greater benefit with CPS ≥10 (HR: 0.66) ✔️ 2-yr EFS: 75% vs 62% #OncTwitter #MedTwitter FDA Oncology OncoAlert

Stage II seminoma: what’s best? JCO 2025. Review compares standard chemo/RT vs novel strategies: RPLND, de-escalated chemo, combo therapy. 👨‍⚕️ Men with IIA/IIB seminoma, LN ≤3 cm ✅ All: >90% cure 🔄 RPLND: relapse 10–30%, avoids chemo/RT in ~70% 1/2 OncoAlert

2️⃣ Metastasis Directed Therapy in Oligometastatic Prostate Cancer 👥 With Maneesh Singh & Piet Ost 🧠 A deep dive into MDT’s role: trial data, timing, integration with systemic Rx. 🚀 Covering both HSPC and CRPC. Read 📖 doi.org/10.1016/j.semr… With an image for the ages!

My 2025 ASTRO GU #radonc spring refresher presentation (+ hidden slides) is available online bit.ly/2025RefresherG… #Refresher25 Rated 5/5 ⭐️⭐️⭐️⭐️⭐️ Send your feedback via QR code or forms.gle/DfyyhhcCCL8EWD…

📊 Are we overestimating success in ph3 oncology trials? 📉 Only 6% of ph3 oncology RCTs show improvement in both OS and QoL. Most “positive” trials rely on surrogate endpoints, often without adjusting QoL for baseline. We must refocus trials on what truly matters to patients.

jamanetwork.com/journals/jaman… TMT for MIBC is a crucial treatment option for our patients. 💵However, its current costs are unsustainable, especially with the growing interest in expanding its use.

'Better technology cures more patients with less side effects' quoting Alison Tree 💙 at the MR and RT symposium in Zurich today! #radiotherapy #ProstateCancer #RadoncGU

ARPI switch is an inferior control arm. What does it take for the GU onc community to stop enrolling patients into these trials using ARPI switch as the control arm? We have talked about this for a long time. It’s sad to keep seeing prostate cancer trials like these in 2025.

Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a phase 3 thelancet.com/journals/lanon… Authors: Alison Tree 💙, Nicholas van As, & Prof Emma Hall The Royal Marsden Cancer Charity, Accuray, The ICR

Brilliant definition of a way to use SBRT/SRS as a strategic tool in cancer treatment management. sciencedirect.com/science/articl…

Local radiotherapy doesn’t improve OS in mHSPC patients, but significantly prolongs time to ADT resistance. Redefining selection criteria is key to identify those who truly benefit in the era of next-generation imaging and modern systemic therapies. sciencedirect.com/science/articl…

Great work out in European Urology Oncology led by Jesus E. Juarez C. outstanding PGY-5 UCLA Jonsson Comprehensive Cancer Center . Pooled analysis of two trials of androgen annihilation (ADT+AAP+apa) and RP/RT plus MDT in de novo mHSPC or oligorecurrent mHSPC euoncology.europeanurology.com/article/S2588-…

Proud to share our ESTRO manifesto published in Radiotherapy & Oncology A call to reposition radiation oncology at the heart of integrated cancer care Open access for 50 days authors.elsevier.com/a/1lRcWcA0-MUMK #RadOnc #ESTRO #OncoAlert OncoAlert sciencedirect.com/science/articl…

In high-risk prostate cancer, radiotherapy plus ADT significantly reduces the risk of distant metastasis compared to surgery-based approaches. However, post-metastasis survival does not differ between treatments. European Urology Oncology Daniel E Spratt OncoAlert Advanced Prostate Cancer Consensus Conference European Association of Urology (EAU)

Microbiota and radiation from the basics 👍👍 nature.com/articles/s4157…